Microbiome Global Market Report 2024

The microbiome market size has grown exponentially in recent years. It will grow from $0.57 billion in 2023 to $0.69 billion in 2024 at a compound annual growth rate (CAGR) of 20.2%. The growth observed in the historical period can be attributed to an increased demand for immunology, rising collaborations, government initiatives, increased healthcare expenditure, and growth in the number of healthcare facilities.

The microbiome market size is expected to see rapid growth in the next few years. It will grow to $1.24 billion in 2028 at a compound annual growth rate (CAGR) of 16.0%. The anticipated growth in the forecast period can be attributed to a rise in healthcare expenditure, an increasing demand for personalized medicine, growing funding, technological advances, and the rising prevalence of chronic diseases. Key trends in the forecast period include the use of artificial intelligence for enhanced analysis and process optimization, strategic collaborations and agreements to expand product portfolios, boost revenues, and establish category leadership. Additionally, there is an emphasis on investing in 3D printing technology for more accurate information and increased efficiency, increasing the number of pipeline studies to develop microbiome therapeutics for various diseases, exploring the development of oncology microbiome therapeutics to maximize revenues, and considering nanotechnology for identifying low-abundant samples to enhance the productivity, efficiency, and accuracy of precision technologies in use.

The growth of the microbiome market is being propelled by the increasing prevalence of inflammatory bowel disease (IBD). IBD comprises a group of chronic inflammatory disorders affecting the digestive tract, particularly the gastrointestinal (GI) tract. The heightened focus on the gut microbiome's role in IBD has spurred research, diagnostics, and therapies centered on the microbiome, fostering the market's expansion. For example, as of February 2021, Temple Health reported that over 1.6 million individuals in the United States are living with IBD, with expectations of a continued increase in prevalence. Consequently, the surge in IBD cases is anticipated to drive the growth of the microbiome market.

The rise in healthcare expenditure is poised to further propel the microbiome market's growth. Healthcare expenditure, encompassing the total amount spent on healthcare services and related activities within a specific healthcare system or economy, plays a crucial role in boosting the microbiome market. Increased investments in microbiome research and development, coupled with growing awareness of the microbiome's significance in human health, are driving the demand for microbiome-based therapies and products. As of May 2023, a report from the Office for National Statistics revealed that healthcare spending in the UK witnessed a 9.4% nominal and 9.7% real-term increase between 2020 and 2021. The total healthcare expenditure in the UK for 2021 amounted to $367.25 billion (£280.7 billion), with pharmaceutical expenditure at $51.84 billion (£39.6 billion) and spending on preventive care at $45.93 billion (£35.1 billion) in 2021, more than doubling from 2020. Thus, escalating healthcare expenditures are a key driver of the microbiome market's growth.

Technological improvement is emerging as a significant trend in the microbiome market. Major companies in the microbiome sector are actively developing advanced technological solutions, such as Seed's introduction of the Probiotic and Prebiotic Daily Synbiotic for both females and males. Seed's Daily Synbiotic adopts a microbe-system strategy, providing strain-specific benefits beyond digestive health, including cardiac safety, dermatological health, immune control, reproductive health, gut barrier integrity, and oxidative stress.

Strategic partnerships are a notable approach employed by major companies in the microbiome market for their growth and development strategies. These partnerships involve leveraging each other's strengths and resources to achieve mutual benefits. For instance, in June 2021, Illumina Inc., a US-based biotechnology company, formed a partnership with Microba Life Sciences Ltd., an Australia-based precision microbiome company. The collaboration aims to combine expertise in next-generation sequencing (NGS) and gut microbiome analysis to enhance data accuracy and comprehensiveness, make microbiome research more accessible in the Asia Pacific and Japan regions, and expedite the development of microbiome-based therapies and diagnostics.

In January 2021, Novozymes, a Denmark-based biotechnology company, acquired Microbiome Labs for an undisclosed amount. This acquisition is a strategic move to expand Novozymes' Human Health platform, providing access to a range of patented solutions and a network of health professionals. Microbiome Labs, a probiotics company, is based in the United States.

Major companies operating in the microbiome market report are Seres Therapeutics, Enterome Bioscience, Ferring Pharmaceuticals, Vedanta BioSciences, Second Genome Inc., Microbiotica, Rebiotix, Inc., Locus Biosciences, Osel Inc., Xbiome Co., Ltd., Microba Life Sciences, Biome Australia, Shoreline Biome, Leucine Rich Bio Pvt Ltd., BugSpeaks, KINS Co., Ltd., Yeda Research and Development Co. Ltd., China National Pharmaceutical Group Corporation, Atlas Biomed, BiomX Ltd., ImmuneBiotech Medical Sweden AB, MetaboGen AB, ADM Biopolis, Viome, PharmaBiome, NCCR Microbiomes, MaaT Pharma, Eligo Bioscience, T3 Pharmaceuticals, MicroBiome Therapeutics LLC, Second Genome, OpenBiome, Microbiome Insights Inc., lallemand Health Solutions, Mybiotics Pharma, DayTwo, Next Biosciences, ViThera Pharmaceuticals Inc., Inqaba Biotechnical Industries (Pty), SNIPR Biome, MyBiome.

North America was the largest region in the microbiome market in 2023. The regions covered in the microbiome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the microbiome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The primary types of microbiomes include bacteria, archaea, viruses, and other microorganisms. Bacteria, single-celled microorganisms belonging to the domain Bacteria, are diverse and abundant life forms found in various environments. Products associated with microbiomes include therapeutics and diagnostics, and technologies such as genomics, proteomics, and metabolomics are employed in conditions such as inflammatory bowel disease, gastrointestinal disorders, metabolic disorders, cancers, and other diseases.

The microbiome market research report is one of a series of new reports that provides microbiome market statistics, including microbiome industry global market size, regional shares, competitors with a microbiome market share, detailed microbiome market segments, market trends, and opportunities, and any further data you may need to thrive in the microbiome industry. This microbiome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The microbiome market consists of sales of firmicutes, bacteroidetes, and actinobacteria. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.